Prognostic Impact of Checkpoint Inhibitor Pneumonitis: Results from a Multicenter Prospective Observational Study (CS-Lung004)
Introduction Checkpoint inhibitor pneumonitis (CIP) is a potentially life-threatening adverse event caused by anti–programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) antibodies. However, paradoxical findings have been reported regarding the association between overall survival (OS) and CIP. This study aimed to prospectively evaluate the relationship between the 2-year OS and CIP in patients receiving first-line treatment, including anti-PD-1/PD-L1 antibody therapy, using 3-month and 1-year landmark analyses. Methods A multicenter prospective observational study was conducted between December 2021 and November 2023 to evaluate the prognostic impact of CIP, based on timing and severity, in patients with non-small cell lung cancer (NSCLC). Results Although no significant difference in OS was observed between patients with and without CIP developed within 2 years or 1 year, the 3-month landmark analysis showed that patients who developed CIP within 3 months had significantly shorter OS than those who did not (median OS from the 3-months landmark: 11.1 months with CIP versus not reached without CIP; log-rank p = 0.011). In multivariate Cox regression analyses, using patients without CIP as the reference group, CIP within 3 months was significantly associated with impaired overall survival (any-grade CIP: hazard ratio [HR] = 2.22, 95% confidence interval [CI]=1.21–4.09; Grade 3–5 CIP: HR=3.37, 95% CI=1.57–7.23). Conclusion This was the first prospective study to demonstrate the prognostic value of CIP. CIP within 3 months after the initiation of first-line treatment, including anti-PD-1/PD-L1 antibody, especially Grade 3–5 CIP, was associated with shorter OS in patients with NSCLC.
Authors
- Jun Yano
- Naoko Matsumoto (ORCID: https://orcid.org/0000-0003-0506-1163)
- Noboru Hattori (ORCID: https://orcid.org/0000-0002-8234-942X)
- Yuko Toyoda (ORCID: https://orcid.org/0000-0002-9124-7978)
- Chihiro Ando (ORCID: https://orcid.org/0000-0003-3775-7536)
- Kakuhiro Yamaguchi (ORCID: https://orcid.org/0000-0002-9117-1934)
- Nobuhiro Kanaji (ORCID: https://orcid.org/0000-0001-7365-4927)
- Koji Kurose (ORCID: https://orcid.org/0000-0002-3878-1477)
- Hiroshi Iwamoto (ORCID: https://orcid.org/0000-0003-4922-5334)
- Yasunari Nagasaki
- Suguru Fujita
- Masaaki Yanai
- Tamio Okimoto (ORCID: https://orcid.org/0000-0001-8295-1296)
- Tetsu Hirakawa (ORCID: https://orcid.org/0009-0007-9091-3397)
- Hisao Higo (ORCID: https://orcid.org/0000-0003-4946-0123)
- Kosuke Oyama (ORCID: https://orcid.org/0000-0003-4335-4450)
- Yoshihiro Taguchi (ORCID: https://orcid.org/0000-0002-1417-9668)
- Kozue Miyazaki
- Shimpei Tada
- Masako Watanabe
Institutions
- Hiroshima University (JP)
- Shimane University (JP)
- Kawasaki Medical School (JP)
- Kagawa University (JP)
- Okayama University Hospital (JP)
- Hiroshima City Asa Citizens Hospital (JP)
- Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital (JP)
- Okayama Red Cross General Hospital (JP)
- Japanese Red Cross Kochi Hospital (JP)
- Tottori University Hospital (JP)
- Hiroshima University Hospital (JP)
- Higashihiroshima Medical Center (JP)
- National Hospital Organization (JP)
- Ehime University (JP)
- Hiroshima City Hiroshima Citizens Hospital (JP)
- Tottori University (JP)
- Kōchi University (JP)
Publication Details
- Journal
- Lung
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1007/s00408-026-00956-1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00